BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yuan GC, Chen AZ, Wang WX, Yi XL, Tu L, Peng F, Qiu ZH. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir. World J Clin Cases 2023; 11(34): 8139-8146 [PMID: 38130795 DOI: 10.12998/wjcc.v11.i34.8139]
URL: https://www.wjgnet.com/2307-8960/full/v11/i34/8139.htm
Number Citing Articles
1
Yongzheng Hu, Yue Zhang, Wei Jiang. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatmentsClinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01584-4
2
Jian-Xing Luo, Guo Chen, Xiao-Yu Hu, Chang Yu. Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysisGastroenterología y Hepatología 2025; 48(4): 502276 doi: 10.1016/j.gastrohep.2024.502276
3
Yu-Xuan Song, Guang-Jun Song, Hui Ma, Bo Feng, Yan-Di Xie. Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced PatientsThe Korean Journal of Gastroenterology 2025; 85(1): 64 doi: 10.4166/kjg.2024.140